First Bancorp (FBNC) Upgraded to “Hold” by BidaskClub Eiger Biopharmaceuticals (EIGR) Stock Rating Lowered by Zacks Investment Research April 26th, 2019 - Comments Off on Eiger Biopharmaceuticals (EIGR) Stock Rating Lowered by Zacks Investment Research - Filed Under - by Latisha Jones Tweet
Eiger Biopharmaceuticals (NASDAQ:EIGR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.
According to Zacks, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. “ Get Eiger Biopharmaceuticals alerts:
Other equities research analysts also recently issued research reports about the stock. ValuEngine raised shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, December 26th. Wedbush reaffirmed a “buy” rating and issued a $43.00 target price on shares of Eiger Biopharmaceuticals in a research note on Tuesday, February 19th. BidaskClub downgraded shares of Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 14th. Finally, Robert W. Baird started coverage on shares of Eiger Biopharmaceuticals in a research note on Monday, January 28th. They issued an “outperform” rating and a $47.00 target price for the company. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Eiger Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $30.88. Shares of NASDAQ:EIGR opened at $11.10 on Thursday. Eiger Biopharmaceuticals has a 52 week low of $8.20 and a 52 week high of $18.00. The company has a quick ratio of 10.16, a current ratio of 10.16 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $213.79 million, a price-to-earnings ratio of -2.91 and a beta of 1.48.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.10). On average, research analysts anticipate that Eiger Biopharmaceuticals will post -2.82 EPS for the current year.
In related news, Director Thomas John Dietz purchased 5,000 shares of Eiger Biopharmaceuticals stock in a transaction dated Monday, April 22nd. The stock was bought at an average price of $11.05 per share, for a total transaction of $55,250.00. Following the completion of the acquisition, the director now directly owns 15,000 shares of the company’s stock, valued at $165,750. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink . Insiders bought 7,477 shares of company stock valued at $83,338 in the last quarter. Corporate insiders own 7.90% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wedbush Securities Inc. acquired a new position in Eiger Biopharmaceuticals during the first quarter worth $179,000. Tibra Equities Europe Ltd acquired a new stake in Eiger Biopharmaceuticals in the first quarter valued at $466,000. Geode Capital Management LLC lifted its stake in Eiger Biopharmaceuticals by 34.9% in the fourth quarter. Geode Capital Management LLC now owns 104,792 shares of the biotechnology company’s stock valued at $1,064,000 after acquiring an additional 27,136 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Eiger Biopharmaceuticals by 127.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,750 shares of the biotechnology company’s stock valued at $373,000 after acquiring an additional 20,625 shares during the last quarter. Finally, 683 Capital Management LLC raised its position in shares of Eiger Biopharmaceuticals by 155.1% in the fourth quarter. 683 Capital Management LLC now owns 1,610,529 shares of the biotechnology company’s stock valued at $16,363,000 after purchasing an additional 979,296 shares during the period. Institutional investors and hedge funds own 78.57% of the company’s stock.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Get a free copy of the Zacks research report on Eiger Biopharmaceuticals (EIGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter . Latest News
